Suven Signs Second Deal With Lilly | Chemical & Engineering News
Volume 86 Issue 11 | p. 23 | Concentrates
Issue Date: March 17, 2008

Suven Signs Second Deal With Lilly

Department: Business

Suven Life Sciences and Eli Lilly & Co. have signed a second drug discovery collaboration in the area of small molecules that treat central nervous system disorders. Suven says it will receive research funding and possible milestone payments ranging from $19 million to $23 million per drug candidate. The two companies signed a similar deal in August 2006.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment